Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Azaserine is a **naturally occurring serine derivative diazo compound** with **antineoplastic** (anti-cancer), **antibiotic**, and **antifungal** properties. It acts primarily as a **purine antagonist** and as a **structural analogue of glutamine**, competitively inhibiting glutamine-dependent enzymatic activities—most notably **glutamine amidotransferase**, a key enzyme in purine biosynthesis and the metabolic hexosamine pathway. Azaserine **inhibits the rate-limiting step of the hexosamine biosynthesis pathway** and **irreversibly inhibits gamma-Glutamyltranspeptidase (GGT1)** by direct interaction at the substrate-binding pocket. It also dampens purine biosynthesis by reacting with cysteine residues in enzyme active sites, and induces DNA damage via formation of carboxymethylated bases and O6-methylguanine. It has been studied as a potential antineoplastic agent, but is not an approved or widely used pharmaceutical. Azaserine is isolated from Streptomyces species[1][2][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on azaserine.